NASDAQ:ARMO - Nasdaq - US04225U1043
49.98
+0.01 (+0.02%)
The current stock price of ARMO is 49.98 null. In the past month the price increased by 0.16%.
ARMO Biosciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company's platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects which induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8 T cells in cancer patients. Its product pipeline includes AM0001, an anti-PD-1 checkpoint inhibitor; AM0003 an anti-LAG-3 checkpoint inhibitor; AM0015 a form of recombinant human Interleukin-15 cytokine and AM0012 a form of recombinant human Interleukin-12 cytokine. ARMO Biosciences, Inc. is based in REDWOOD CITY, United States.
ARMO BIOSCIENCES INC
575 Chesapeake Drive
Redwood City CA 94063
CEO: Peter Van Vlasselaer
Phone: 650-779-5075
The current stock price of ARMO is 49.98 null. The price increased by 0.02% in the last trading session.
The exchange symbol of ARMO BIOSCIENCES INC is ARMO and it is listed on the Nasdaq exchange.
ARMO stock is listed on the Nasdaq exchange.
ARMO BIOSCIENCES INC (ARMO) has a market capitalization of 1.52B null. This makes ARMO a Small Cap stock.
ARMO BIOSCIENCES INC (ARMO) has a support level at 49.97 and a resistance level at 49.98. Check the full technical report for a detailed analysis of ARMO support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ARMO does not pay a dividend.
ARMO BIOSCIENCES INC (ARMO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-28.52).
ChartMill assigns a technical rating of 6 / 10 to ARMO.
ChartMill assigns a fundamental rating of 3 / 10 to ARMO. The financial health of ARMO is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ARMO reported a non-GAAP Earnings per Share(EPS) of -28.52. The EPS decreased by -8.7% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -24.23% | ||
ROE | -27.05% | ||
Debt/Equity | 0 |